Needham Reiterates Buy on Autolus Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintained a $7 price target for the company's stock.
November 29, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Autolus Therapeutics and maintains a $7 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating by a reputable analyst like Gil Blum from Needham tends to instill confidence in investors and can lead to a positive short term impact on the stock price. The maintenance of a $7 price target suggests that the analyst sees potential for the stock to rise to that level, which is a bullish signal for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100